Company intelligence / Profile preview

ExoRNA Bio

Taipei, Taiwan

Ownership: Private
Development stage: Other

Overview

ExoRNA Bio is a biotechnology company specializing in the development of circular RNA (circRNA) therapies delivered via exosomes. The company's proprietary platform combines the structural stability and prolonged protein expression of circRNA with the natural delivery advantages of exosomes, such as low immunogenicity and tissue-specific targeting. ExoRNA Bio aims to overcome the limitations of current mRNA and lipid nanoparticle (LNP) technologies to provide more effective treatments for oncology, rare diseases, and other genetic conditions. The company is currently advancing multiple programs through the pre-clinical stage, focusing on high-potency and durable therapeutic outcomes.

Therapeutic areas: OncologyRare Diseases
Modalities: Circular RNAExosome-based therapyRNA therapy
Industry: Biotech

Beyond the preview

Go deeper on ExoRNA Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ExoRNA Bio.

Explore the full profile